FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155220017> ?p ?o ?g. }

• W2155220017 endingPage "652" @default.
• W2155220017 startingPage "645" @default.
• W2155220017 abstract "OBJECTIVE—Growing evidence supports that nonenzymatic glycation products may cause hyperglycemia-induced diabetes complications. Amadori-modified proteins are the intermediate products of nonenzymatic glycation and constitute the forms of glycated proteins in diabetes. The objective of the current study was to utilize two-dimensional gel electrophoresis, Western blot, and mass spectrometry to identify Amadori-modified plasma proteins in type 2 diabetic patients with poor glycemic control and assess the impact of short-term insulin treatment on the glycation of these proteins. RESEARCH DESIGN AND METHODS—We compared eight type 2 diabetic subjects (aged 56 ± 3 years and BMI 29.7 ± 0.9 kg/m2) with an average diabetes duration of 8.5 years (range 3–19) with equal numbers of weight-matched (aged 56 ± 2 years and BMI 30.1 ± 10.0 kg/m2) and lean (aged 58 ± 2 years and BMI 25 ± 00.5 kg/m2) nondiabetic subjects who have no first-degree relatives with diabetes. Two separate blood samples were collected from the type 2 diabetic subjects, one following 2 weeks of withdrawal of all antidiabetic medications (T2D−; plasma glucose 12.6 ± 1.0 mmol/l) and another following 10 days of intensive insulin treatment (T2D+; plasma glucose 5.5 ± 0.2 mmol/l). Plasma proteins were separated using single and two-dimensional gel electrophoresis. Western blot analysis was performed, and several proteins, which reacted with the Amadori-antibody (1-deoxyfructosyl lysine), were identified by tandem mass spectrometry. RESULTS—No significant differences in the glycation of proteins between the obese and lean groups were noted, but type 2 diabetic patients had several proteins with higher glycation than the control groups. We identified 12 plasma proteins with reduced reaction to the anti-Amadori antibody upon intensive insulin treatment. A significant (P &lt; 0.03) difference in Amadori modification was observed between the T2D− and control subjects for all these proteins except the Ig light chain. Insulin treatment reduced Amadori modification of albumin (23.2%, P &lt; 0.02), fibrin (34.6%, P &lt; 0.001), Ig heavy chain constant region (20.7%, P &lt; 0.05), transferrin (25.4%, P &lt; 0.04), and Ig light chain (13%, P &lt; 0.02). In addition, Western blot analysis of two-dimensional gel electrophoresis identified α-fibrinogen precursor, β-fibrinogen precursor, fibrinogen γ-B chain precursor, hemopexin, vitamin D binding protein, and serine protease inhibitor as proteins with a reduced reaction to anti-Amadori antibody upon intensive insulin treatment. CONCLUSIONS—The current approach offers the opportunity to identify Amadori modification of many proteins that may cause functional alterations and offers the potential for monitoring short-term glycemic control in diabetic patients." @default.
• W2155220017 created "2016-06-24" @default.
• W2155220017 creator A5002287349 @default.
• W2155220017 creator A5012800116 @default.
• W2155220017 creator A5013310684 @default.
• W2155220017 creator A5027069082 @default.
• W2155220017 creator A5081374792 @default.
• W2155220017 creator A5090076487 @default.
• W2155220017 date "2005-03-01" @default.
• W2155220017 modified "2023-09-26" @default.
• W2155220017 title "Identification of Amadori-Modified Plasma Proteins in Type 2 Diabetes and the Effect of Short-Term Intensive Insulin Treatment" @default.
• W2155220017 cites W1517694645 @default.
• W2155220017 cites W1561751955 @default.
• W2155220017 cites W1562556996 @default.
• W2155220017 cites W1591116859 @default.
• W2155220017 cites W1976068063 @default.
• W2155220017 cites W1977879939 @default.
• W2155220017 cites W1989540914 @default.
• W2155220017 cites W1998614770 @default.
• W2155220017 cites W2012769886 @default.
• W2155220017 cites W2013633841 @default.
• W2155220017 cites W2022939284 @default.
• W2155220017 cites W2034124474 @default.
• W2155220017 cites W2038912720 @default.
• W2155220017 cites W2044437167 @default.
• W2155220017 cites W2050214517 @default.
• W2155220017 cites W2051493401 @default.
• W2155220017 cites W2052831166 @default.
• W2155220017 cites W2056258976 @default.
• W2155220017 cites W2056560852 @default.
• W2155220017 cites W2063090432 @default.
• W2155220017 cites W2067713279 @default.
• W2155220017 cites W2073858554 @default.
• W2155220017 cites W2080904568 @default.
• W2155220017 cites W2086204200 @default.
• W2155220017 cites W2091131126 @default.
• W2155220017 cites W2110817868 @default.
• W2155220017 cites W2113689119 @default.
• W2155220017 cites W2114283061 @default.
• W2155220017 cites W2125624587 @default.
• W2155220017 cites W2142296386 @default.
• W2155220017 cites W2167818045 @default.
• W2155220017 cites W2313527545 @default.
• W2155220017 cites W2323043584 @default.
• W2155220017 cites W2337292567 @default.
• W2155220017 cites W2769264260 @default.
• W2155220017 cites W4229765886 @default.
• W2155220017 cites W4247855171 @default.
• W2155220017 doi "https://doi.org/10.2337/diacare.28.3.645" @default.
• W2155220017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15735202" @default.
• W2155220017 hasPublicationYear "2005" @default.
• W2155220017 type Work @default.
• W2155220017 sameAs 2155220017 @default.
• W2155220017 citedByCount "62" @default.
• W2155220017 countsByYear W21552200172012 @default.
• W2155220017 countsByYear W21552200172013 @default.
• W2155220017 countsByYear W21552200172014 @default.
• W2155220017 countsByYear W21552200172015 @default.
• W2155220017 countsByYear W21552200172016 @default.
• W2155220017 countsByYear W21552200172017 @default.
• W2155220017 countsByYear W21552200172018 @default.
• W2155220017 countsByYear W21552200172019 @default.
• W2155220017 countsByYear W21552200172020 @default.
• W2155220017 countsByYear W21552200172022 @default.
• W2155220017 countsByYear W21552200172023 @default.
• W2155220017 crossrefType "journal-article" @default.
• W2155220017 hasAuthorship W2155220017A5002287349 @default.
• W2155220017 hasAuthorship W2155220017A5012800116 @default.
• W2155220017 hasAuthorship W2155220017A5013310684 @default.
• W2155220017 hasAuthorship W2155220017A5027069082 @default.
• W2155220017 hasAuthorship W2155220017A5081374792 @default.
• W2155220017 hasAuthorship W2155220017A5090076487 @default.
• W2155220017 hasBestOaLocation W21552200171 @default.
• W2155220017 hasConcept C118094880 @default.
• W2155220017 hasConcept C126322002 @default.
• W2155220017 hasConcept C134018914 @default.
• W2155220017 hasConcept C146543888 @default.
• W2155220017 hasConcept C147990577 @default.
• W2155220017 hasConcept C2777180221 @default.
• W2155220017 hasConcept C2779306644 @default.
• W2155220017 hasConcept C2780221984 @default.
• W2155220017 hasConcept C2780473172 @default.
• W2155220017 hasConcept C555293320 @default.
• W2155220017 hasConcept C71924100 @default.
• W2155220017 hasConceptScore W2155220017C118094880 @default.
• W2155220017 hasConceptScore W2155220017C126322002 @default.
• W2155220017 hasConceptScore W2155220017C134018914 @default.
• W2155220017 hasConceptScore W2155220017C146543888 @default.
• W2155220017 hasConceptScore W2155220017C147990577 @default.
• W2155220017 hasConceptScore W2155220017C2777180221 @default.
• W2155220017 hasConceptScore W2155220017C2779306644 @default.
• W2155220017 hasConceptScore W2155220017C2780221984 @default.
• W2155220017 hasConceptScore W2155220017C2780473172 @default.
• W2155220017 hasConceptScore W2155220017C555293320 @default.
• W2155220017 hasConceptScore W2155220017C71924100 @default.
• W2155220017 hasIssue "3" @default.
• W2155220017 hasLocation W21552200171 @default.
• W2155220017 hasLocation W21552200172 @default.

• next